Event
Oxford-Harrington Rare Disease Centre Symposium 2026
23rd - 24th September, 2026
- Additional Details:
Save the date for the Oxford-Harrington Rare Disease Centre Symposium coming in September 2026. Subscribe to the OHC newsletter to receive more details and a programme in the coming months.
Confirmed Speakers
Wednesday, 23rd of September, 2026
- Fyodor Urnov, Professor of Molecular Therapeutics, UC Berkeley
- Sarah Tabrizi, Professor of Clinical Neurology & Neurogenetics, University College London
- Patrick Chinnery, Professor of Neurology, University of Cambridge
- Nicola Blackwood, Chair, Genomics England Limited; Chair, Health Data Research Service; Chair, Oxford University Innovation
- Katherine Bainbridge, Head of Rare Diseases and Emerging Therapies, Department of Health and Social Care
- Rebecca Ahrens-Nicklas, Assistant Professor of Pediatrics, Children’s Hospital of Philadelphia
- Hugh Watkins, Professor of Cardiovascular Medicine, University of Oxford
- Harriet Holme, Executive Chair, PCD Research; Drug Development Clinician, Weatherden
- Metin Avkiran, Director of International Research Partnerships and Special Programmes, British Heart Foundation
- Tony Wood, Chief Scientific Officer, GSK
- Martin Murphy, Executive Chair, Cora Biosciences
Thursday, 24th of September, 2026
- Moin Saleem, Professor of Paediatric Renal Medicine, University of Bristol
- Haiyan Zhou, Professor of Genetic Medicine, University College London
- Francesco Muntoni, Chair of Paediatric Neurology, University College London
- Dan O’Connor, Director, Regulatory Policy & Early Access, Association of the British Pharmaceutical Industry
- Matthew Anderson, Co-Director, Oxford-Harrington Rare Disease Centre
- John Anderson, Professor of Experimental Paediatric, Oncology, University College London
- John Letterio, Director, Angie Fowler Adolescent and Young Adult Cancer Institute at UH Rainbow Babies and Children’s Hospital
- Stephanie Manton, Chief Scientific Officer, WinQure
- Charles Gersbach, Professor of Biomedical Engineering, Duke University
- Xianxin Hua, Professor of Cancer Biology, University of Pennsylvania
- Jonathan Bracey, Founder, MVA Society
- David Hipkiss, Executive Chair, AlveoGene
- Kylie Bromley, VP, General Manager & Managing Director, UK & Ireland, Biogen
- Azad Bonni, Head of Pharma Research & Early Development, Roche
- Roxana Redis, Group Leader, Advanced Modalities, Charles River Laboratories
- Martin Pool, Hospital Pharmacist and Translational Scientist, Leiden University Medical Center
- Gregory Costain, Staff Physician, The Hospital for Sick Children, Toronto, Canada